Regentis Biomaterials Ltd.
RGNT· NYSE
Who holds Regentis Biomaterials Ltd., from the managers’ Form 13F reports for the quarter ended Sep 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | 701.7K | ±0% | $1.3M | 0.4% | Nov 16, 2026 |
| Warberg Asset Management LLC | 58.5K | −32.7% | $108.9K | 0.1% | Nov 2, 2026 |
| Citadel Advisors LLC | 58.9K | New | $106.7K | 0% | Nov 16, 2026 |
| Jane Street Group, LLC | 43.2K | −0.2% | $78.3K | 0% | Nov 12, 2026 |
| Marex Group Ltd | 29.4K | New | $53.2K | 0.1% | Nov 16, 2026 |
| UBS Group AG | 1.2K | +187.1% | $2.3K | 0% | Nov 10, 2026 |